VASCULAR BIOGENICS LTD (VBLT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:VBLT • IL0011327454

0.156 USD
-0.02 (-8.77%)
At close: Oct 16, 2023
0.168 USD
+0.01 (+7.69%)
After Hours: 10/16/2023, 8:02:23 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VBLT. VBLT was compared to 524 industry peers in the Biotechnology industry. While VBLT seems to be doing ok healthwise, there are quite some concerns on its profitability. VBLT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year VBLT has reported negative net income.
  • In the past year VBLT has reported a negative cash flow from operations.
VBLT Yearly Net Income VS EBIT VS OCF VS FCFVBLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

  • VBLT has a worse Return On Assets (-64.74%) than 64.62% of its industry peers.
  • VBLT's Return On Equity of -82.94% is in line compared to the rest of the industry. VBLT outperforms 46.35% of its industry peers.
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROIC N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
VBLT Yearly ROA, ROE, ROICVBLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100

1.3 Margins

  • VBLT's Gross Margin of 96.47% is amongst the best of the industry. VBLT outperforms 97.01% of its industry peers.
  • VBLT's Gross Margin has declined in the last couple of years.
  • VBLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
VBLT Yearly Profit, Operating, Gross MarginsVBLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

  • VBLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VBLT has been increased compared to 1 year ago.
  • There is no outstanding debt for VBLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VBLT Yearly Shares OutstandingVBLT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
VBLT Yearly Total Debt VS Total AssetsVBLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -16.80, we must say that VBLT is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -16.80, VBLT is doing worse than 87.54% of the companies in the same industry.
  • VBLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC8.55%
VBLT Yearly LT Debt VS Equity VS FCFVBLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • VBLT has a Current Ratio of 4.63. This indicates that VBLT is financially healthy and has no problem in meeting its short term obligations.
  • VBLT has a Current ratio (4.63) which is in line with its industry peers.
  • VBLT has a Quick Ratio of 4.63. This indicates that VBLT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.63, VBLT is in line with its industry, outperforming 45.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.63
VBLT Yearly Current Assets VS Current LiabilitesVBLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

  • VBLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.41%, which is quite impressive.
  • Looking at the last year, VBLT shows a very negative growth in Revenue. The Revenue has decreased by -15.91% in the last year.
  • VBLT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -45.64% yearly.
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to decrease by -11.84% on average over the next years. This is quite bad
  • VBLT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.94% yearly.
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VBLT Yearly Revenue VS EstimatesVBLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VBLT Yearly EPS VS EstimatesVBLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VBLT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VBLT Price Earnings VS Forward Price EarningsVBLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VBLT Per share dataVBLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • VBLT's earnings are expected to decrease with -15.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for VBLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VASCULAR BIOGENICS LTD

NASDAQ:VBLT (10/16/2023, 8:02:23 PM)

After market: 0.168 +0.01 (+7.69%)

0.156

-0.02 (-8.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-13
Inst Owners0%
Inst Owner Change0%
Ins Owners8.48%
Ins Owner Change0%
Market Cap12.11M
Revenue(TTM)481.00K
Net Income(TTM)-15.96M
Analysts45.71
Price Target5.1 (3169.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.18
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.01
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.47%
FCFM N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.68%
Cap/Sales 6.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.63
Altman-Z -16.8
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)65.86%
Cap/Depr(5y)79.11%
Cap/Sales(3y)106.53%
Cap/Sales(5y)142.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.09%
OCF growth 3YN/A
OCF growth 5YN/A

VASCULAR BIOGENICS LTD / VBLT FAQ

Can you provide the ChartMill fundamental rating for VASCULAR BIOGENICS LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VBLT.


Can you provide the valuation status for VASCULAR BIOGENICS LTD?

ChartMill assigns a valuation rating of 0 / 10 to VASCULAR BIOGENICS LTD (VBLT). This can be considered as Overvalued.


Can you provide the profitability details for VASCULAR BIOGENICS LTD?

VASCULAR BIOGENICS LTD (VBLT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for VASCULAR BIOGENICS LTD?

The Earnings per Share (EPS) of VASCULAR BIOGENICS LTD (VBLT) is expected to decline by -15.38% in the next year.